QUIDELORTHO CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
QUIDELORTHO CORP (QDEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $51.57 per share for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2026-02-19
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2025 was $51.57, a 38.20% decline from fiscal 2024.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $83.45, a 12.31% decline from fiscal 2023.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $95.16, a 5.50% decline from fiscal 2023.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $100.70.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|
| 2025-12-28 | $51.57 10-K · filed 2026-02-19 | |
| 2024-12-29 | $83.45 10-K · filed 2025-02-27 | |
| 2023-12-31 | $95.16 10-K/A · filed 2024-08-01 | |
| 2023-01-01 | $100.70 10-K · filed 2023-02-23 | |
| 2022-10-02 | $104.18 10-Q · filed 2022-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |